A pioneering clinical study has found that providing pluripotent cells to developing infants diagnosed with spina bifida as part of a surgical repair may represent a "major milestone" in treating birth defects.
Trial Details and Safety
The US-based trial focused on six fetuses with the 'open' form of spina bifida. Surgeons applied mother's placental stem cells to the surface of the baby's spinal cord during the repair procedure.
Critically, the cell therapy was found to be safe. Doctors verified that the cells did not cause cancerous growths, disrupt the healing process, or prevent the reversal of co-occurring hindbrain herniation.
Promising Outcomes
Post-birth MRI scans indicated a complete reversal of hindbrain herniation in all six infants. This neurological improvement is strongly associated with better mobility and function.
"In the event it allows a greater number of infants to achieve ambulation who otherwise would not, it may emerge as the new treatment paradigm," noted the study director. "The outcomes appear profoundly encouraging and pave the way for lots of potential new treatments."
Future Implications and Hope
Commentators reviewing the findings indicated that subsequent studies of these noted improvements could herald a "fresh chapter" in fetal surgery. The possibility of ameliorating neurological damage present before birth is regarded as a revolutionary objective.
Notably important would be advancements for urogenital and gastrointestinal outcomes, which are frequent complications for people affected by this defect.
The Path Forward
Despite this being a first-in-human effort involved a limited number of patients, its confirmed tolerability and hopeful trends create a solid basis for broader investigative efforts. The addition of cellular treatment with established fetal surgery techniques presents significant potential for transforming outcomes for babies yet to be born with spina bifida.